Prosecutors begin opening statements in the trial of Charlie Javice after two days of jury selection.
Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback